Variable Response to Chemotherapeutics by a Subpopulation of MCF-7 Breast Cancer Cells by Dorland, Julie
  
 
 
Variable Response to 
Chemotherapeutics by a 
Subpopulation of MCF-7 
Breast Cancer Cells 
 
JULIE MARIE DORLAND 
BIOMEDICAL ENGINEERING AND PLAN II HONORS 
 
 
 
 
 
 
 
MAY 17, 2016 
ENGINEERING HONORS UNDERGRADUATE THESIS 
DEPARTMENT OF BIOMEDICAL ENGINEERING 
THE UNIVERSITY OF TEXAS AT AUSTIN 
AUSTIN, TX 78712 
  
 
 
 
 
DR. AMY BROCK, PH.D. 
DEPARTMENT OF BIOMEDICAL ENGINEERING 
FACULTY SUPERVISOR 
 
 
 
 
 
 
DR. JANET ZOLDAN, PH.D. 
DEPARTMENT OF BIOMEDICAL ENGINEERING 
SECOND READER  
i 
 
Table of Contents 
List of Figures…………………………………………………………………………………..…ii 
Abstract……………………………………………………………………………………………1 
Introduction………………………………………………………………………………………..2 
Materials and Methods…………………………………………………………………………….8 
 Cell Culture……………………………………………………………………………..…8 
 Doxorubicin Treatment……………………………………………………………………8 
  Spiky Cell Induction……………………………………………………………....8 
  Spiky Cell Characterization…………………………………………………….....9 
 Cell Imaging……………………………………………………………………………...11 
 Quantification of Proliferation…………………………………………………………...11 
 Invasion Assay…………………………………………………………………………...11 
 Staining Cells…………………………………………………………………………….13 
 Dose Response Assay……………………………………………………………………15 
Results……………………………………………………………………………………………17 
Treatment of Cells with Doxorubicin and Imaging Phenotypes During Recovery from 
Doxorubicin Treatment…………………………………………………………………..17 
Proliferation During Recovery from Doxorubicin Treatment…………………………...20 
Drug Sensitivity During Recovery from Doxorubicin Treatment……………………….22 
Invasive Potential of Cells Following Doxorubicin Treatment………………………….25 
 Staining for Biomarkers Labelling Resistant Cells……………………………………....28 
Discussion and Conclusion………………………………………………………………………30 
Acknowledgements………………………………………………………………………………37 
References………………………………………………………………………………………..38 
ii 
 
List of Figures 
Figure 1. Schematic of Experimental Design……………………………………………………10 
Figure 2. Quantification of Morphology Changes Arising from Doxorubicin Treatment………19 
Figure 3. Proliferation During Recovery from Doxorubicin Treatment…………………………21 
Figure 4. Drug Sensitivity During Recovery from Doxorubicin Treatment……………………..24 
Figure 5. Invasive Potential During Recovery from Doxorubicin Treatment……………….......27 
Figure 6. Immunocytochemistry Staining for E-Cadherin……………………………………....29 
  
1  
 
Abstract 
Several different morphologies can be observed in a population of MCF-7 breast cancer cells, 
but the typical epithelial morphology vastly predominates. After treatment with the 
chemotherapeutic doxorubicin, the proportion of abnormal morphologies greatly increases. Over 
the course of recovery from this drug treatment, the population returns back to high proportions 
of the normal morphologies. However, previous studies in the Brock lab have shown that in rare 
instances after recovery from doxorubicin treatment, a phenotype termed the "spiky cells" 
became stable at higher proportions. This population of spiky cells appeared to have 
characteristics associated with drug-resistant and metastatic cell populations. In this thesis, I 
tested the aggressive tumor characteristics of this stable spiky subpopulation and whether it 
responds differently to doxorubicin. I hypothesized that the growth rate, invasiveness, and drug 
sensitivity of this population would more closely resemble aggressive tumor cells compared with 
the naïve MCF-7 population. First, I repeated the induction of the spiky subpopulation with a 
larger sample size, to determine how frequently this spiky subpopulation occurred. Second, I 
characterized this subpopulation by comparing four groups: untreated controls of both the normal 
MCF-7 population and the stable spiky population as well as groups from both populations 
treated with the same concentration of doxorubicin. I performed these comparisons over the 8-
week course of recovery from the treatment. These tests included proliferation rate calculations, 
invasion assays, staining for a critical protein component of cell-cell junctions, and drug 
sensitivity tests.  We found that the spiky subpopulation appeared more aggressive and resistant, 
with higher invasion and proliferation, fewer surface markers related to cell connections, and 
decreased drug sensitivity.   
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Introduction 
Breast cancer is a difficult disease to treat. Of patients with early-stage breast cancer, 
approximately 30% have recurrent disease, and this is often metastatic.
1
 The majority of patients 
receive surgery to remove the primary tumor, and many patients receive a neoadjuvant therapy 
before surgery to reduce the size of the tumor or an adjuvant therapy after surgery to remove 
remaining tumor cells.
2
 These additional therapies often include cytotoxic chemotherapeutics 
such as anthracycline drugs.
1
 Even patients with a good prognosis may still have an early 
recurrence of breast cancer. This is due to cancer cell resistance to the chemotherapy drugs, and 
it has been found that individual cell characteristics create this resistance.
1
  
Anthracycline drugs, such as doxorubicin, inhibit DNA replication by intercalating into 
the DNA.
3
 This prevents the synthesis of cellular proteins, leading to cell death. Doxorubicin 
also prevents the process of DNA repair by ligation of broken strands and inhibits topoisomerase 
II, making it easier for DNA to be cleaved.
4,5
 Doxorubicin is often used, by itself or in addition 
to other drugs, to treat several forms of cancer, including breast cancer.
6
  
For many years, it has been the predominant view in cancer research that tumors are 
formed by cancer cells that acquire a favorable mutation.
7
 This population would then expand 
clonally and acquire genetic and epigenetic changes to increase its malignancy. However, it has 
been shown that even cells that are genetically identical can exhibit heterogeneity in their protein 
expression, and cancer researchers have more recently argued that non-genetic variability could 
be selected for in cancer cell evolution rather than genetic variability.
7
 In order for this non-
genetic variability to be selected for by Darwinian evolution, this individuality must be passed on 
to daughter cells. The heterogeneity of these cancer cells causes them to respond differently to 
the tumor environment.
7
 This heterogeneity can be explained by gene regulatory networks, 
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which regulate a cell’s gene expression. Different cell states are defined by “discrete, stable, self-
organizing gene expression patterns,” and the stable states, termed “attractor states,” are 
analogous to equilibrium states of minimal energy. Each attractor state corresponds to a gene 
expression profile, and the genetic network has a large number of these stable attractor states 
with varying gene expression. Sub-attractor states also exist around a central attractor state, and 
these sub-attractor states can cause gene expression heterogeneity by trapping a cell on its way to 
the central attractor state. Heterogeneity in gene expression can manifest in differences in 
observed phenotype. For example, it has been found that individual cancer cells from the same 
clonal tumor vary in their malignancy.
7
 Because this heterogeneity is dynamic, it could 
potentially be explained by gene regulatory networks.
7
 Studies of melanoma have found that 
phenotypic heterogeneity in the tumor cells primarily arises from upregulation and 
downregulation of a range of markers.
8
 
Drug resistance is a problem with any type of chemotherapy treatment, and there are two 
types of resistance: acquired resistance and intrinsic resistance.
9
 In acquired resistance, the drug 
loses effectiveness over time, and in intrinsic resistance the drug is ineffective when the patient 
first receives it. Breast cancer patients often acquire resistance to chemotherapeutics, which 
reverses the previous success of their chemotherapeutic treatment.
9
 In fact, many different 
cancers have been found to have this acquired resistance, where patients will respond well to a 
therapy but, after a break from the treatment, will then experience therapy failure the second 
time.
10
 Studies have found that cancer cell resistance to chemotherapeutics can be due to genetic, 
epigenetic, or microenvironmental factors.
11
 Some researchers have found that there are certain 
genes for which adjustment in expression can cause increased resistance, and this increased 
resistance is often related to intracellular pathways related to growth, survival, differentiation, 
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and apoptosis.
11
 It is necessary to understand the mechanisms by which breast tumors become 
resistant to chemotherapeutics and what cellular changes accompany this resistance in order to 
combat the problem of resistance when treating breast cancer. This study aims to examine 
characteristics of tumor aggression, such as resistance, in subpopulations of MCF-7 breast cancer 
cells in order to understand the effect of doxorubicin on the cells.  
Many researchers have argued that chemotherapeutic treatments kill off the majority of 
cancer cells, leaving a small population of cells which happened to have a resistance-conferring 
mutation and which then clonally divide to repopulate the tumor.
12
 However, the idea of non-
genetic heterogeneity calls this theory into question. It has been found that cancer cells shift 
between different attractor states, some of which are cancer stem-cell-like states, in which cells 
naturally are more resistant to drugs. The cancer cells can switch between these attractor states 
spontaneously or due to external perturbation. Spontaneous switching allows for Darwinian 
selection of cells that happen to be more resistant to chemotherapeutics due to non-genetic 
heterogeneity. Daughter cells can inherit these resistant cell states even though they are not due 
to genetic changes, and this allows for the expansion of a subpopulation of the cancer cells, 
which then increases the probability of genetic mutations. The other mechanism of switching 
between cell states is by external signals caused by a perturbation. In this method of resistance 
development, cells enter a resistant cell state due to the introduction of the chemotherapeutic. 
These non-genetic changes can also be inherited by daughter cells, and this is an example of 
Lamarckian evolution.
12
  
Examples of these stable attractor states in cancer cells include the mesenchymal and 
epithelial developmental states.
12
 Epithelial cells are typically adherent and connected to the 
basement membrane.
13
 The MCF-7 human breast cancer cell line used in these experiments is an 
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epithelial cell line. Mesenchymal cells are cells that have become mobile and invasive and are 
more resistant to apoptosis.
13
 It is possible for cells to switch between these states, and this is 
called epithelial to mesenchymal transition (EMT). EMT has been found to correlate with tumor 
progression, and both EMT and chemotherapeutic resistant cell states have been shown to be 
reversible transitions.
8
 
Proliferation rate is a measure of how quickly the cells are dividing, and a high cancer 
cell proliferation rate is a mark of an aggressive breast tumor.
14
 In vivo, different tumors have 
different proliferation responses to chemotherapeutics: in one study, some tumors rose in 
proliferation after treatment, some decreased, and some stayed the same.
15
 In another patient 
study, it was found that cells that are drug-sensitive have repressed growth immediately after 
treatment, but weeks later, the growth increased again.
16
 Studies on the effect of doxorubicin on 
MCF-7 cells found that at a concentration of 1 µM, cell growth was reduced by 75% when 
compared to untreated cells, and after 72 hours there were 40% fewer viable cells.
17
 However, 
this study did not assess the long-term effects of the doxorubicin treatment on proliferation.  
Researchers in the Brock lab found previously that after treating MCF-7 cells with 
doxorubicin, high proportions of abnormal morphologies arose in the surviving cell population. 
They hypothesized that these other morphologies represent different attractor states and the 
phenotypic changes are due to non-genetic heterogeneity. One of these abnormal phenotypes was 
termed the "spiky cells” (Figure 1). These cells have long, spindly projections. The typical MCF-
7 morphology is epithelial, with cells forming close connections to their neighbors, but the spiky 
cells do not form as many connections. Normally, after treatment with doxorubicin the cells 
eventually return to the typical morphology proportions found in untreated cells: the vast 
majority of cells have the normal phenotype, with a small percentage of cells having the 
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abnormal morphologies. However, in rare cases, after treatment, rather than recovering back to 
normal proportions, the spiky cells become stable at higher-than-normal proportions.  
In these studies, I compared four treatment groups (Figure 1): untreated controls of both a 
naïve MCF-7 population (termed untreated normal) and a population that had become stably 
spiky at around 30% spiky (termed stable spiky) as well as a group from each of these 
populations which was treated for 24 hours with 500 nM doxorubicin (treated normal and treated 
spiky). This dose was chosen because previous studies in the lab found that a 500 nM dose of 
doxorubicin caused higher proportions of morphology changes than did lower doses. Over the 
course of the cells' recovery from this doxorubicin treatment, I assessed four characteristics 
pertaining to tumor aggression. I compared the proliferation of the populations because more 
aggressive tumors proliferate more quickly. I tested dose response, which is a measure of how 
resistant the cells are to doxorubicin, and more aggressive tumors are more resistant to 
chemotherapeutics. I tested the invasive potential of the different populations because invasion 
into the surrounding extracellular matrix is a key aspect of cancer progression. And finally, I 
used immunocytochemistry to determine the amount and localization of the protein E-cadherin, a 
cell-cell junction marker related to invasion and mobility. Cells that have fewer cell-cell 
junctions are typically more mobile and invasive because they are not as tightly connected to the 
cells around them. In addition to these experiments, I also attempted to repeat the induction of 
the stable spiky phenotype population, in order to determine at what percentage the cell 
populations recover to high numbers of spiky cells.  
Based on initial observations, we hypothesized that the stable spiky population would 
show more aggressive tumor characteristics than would the untreated normal MCF-7 population. 
In comparison with the naïve MCF-7 cells, we believed that the stable spiky cells would be more 
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proliferative, show increased doxorubicin resistance, have a higher invasive potential, and have 
fewer cell-cell junctions as demonstrated by lower E-cadherin expression. We expected that the 
doxorubicin treatment would also have an effect on these characteristics – we hypothesized that 
the treated groups would be less proliferative at the beginning of the recovery, more resistant, 
more invasive, and have lower E-cadherin expression than their untreated control.  
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Materials and Methods 
 
Cell Culture 
The MCF-7 human breast cancer cell line is commercially available. The MCF-7 culture 
media used in these experiments was composed of 89% Minimal Essential Media (MEM, Gibco 
Lot #1663071), 10% Fetal Bovine Serum (FBS, Gibco Lot #1708457), and 1% Penicillin-
Streptomycin (Pen-Strep, Gibco Lot #1601706).  
Media was changed every other day. Before replacing the media, the cells were washed 
with 1X Phosphate Buffered Saline, (PBS, HyClone Lot #AAE202584). Untreated cells were 
passaged using trypsin-EDTA (Gibco Ref #25300-054) once a week. Treated cells were 
passaged when they became approximately 80% confluent.  
 
Doxorubicin Treatment 
Doxorubicin is a chemotherapeutic, and its handling and disposal adhered to the 
guidelines set by the University Environmental Health and Safety Department.  
Spiky Cell Induction: For the spiky cell induction experiment, we plated 100,000 normal, 
untreated, low-passage MCF-7 cells into each well of four 6-well tissue culture-treated plates. 
After allowing the cells to grow for two days, these cells were treated with a 500 nM dose of 
doxorubicin for 24 hours. The stock solution of 2048 nM doxorubicin was diluted in MCF-7 
media, and 3 mL of this doxorubicin-media solution was added to each well. After 24 hours, 
cells were washed with PBS and further cultured in regular media. These plates were passaged 
once a week and supplied with fresh media twice a week. Each time they were passaged, three of 
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the plates were randomly selected to be counted, and these counts were averaged each week. 
After two weeks, eight of the flasks were left in the incubator and were no longer passaged or 
replenished with fresh media, and the 16 remaining flasks were still passaged and fed each week. 
Periodic images were taken each week of several flasks, and after 4 weeks each flask was 
imaged to assess the proportion of spiky cell morphology. 
Spiky Cell Characterization: For the characterization experiments comparing the spiky 
cells to normal cells (Figure 1), both untreated normal and stable spiky cells were plated on 10 
cm and 15 cm cell culture plates. These plates were treated with a 500 nM dose of doxorubicin 
for 24 hours. The stock solution of 2048 nM doxorubicin was diluted in MCF-7 media, and 10 
mL of this doxorubicin-media solution was added to each 10 cm plate and 30 mL was added to 
each 15 cm plate. After the 24-hour treatment, cells were cultured in normal MCF-7 media. 
Images were taken of several plates and the media in all plates was replaced three times a week. 
Each week, several of the plates were passaged in order to use the cells in characterization 
experiments. Throughout this experiment, we kept untreated controls of both the normal and 
spiky cells. 
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Figure 1 | Schematic of Experimental Design. Typical MCF-7 cells display the cobblestone 
epithelial phenotype, while the spiky cells form spindle-like projections and do not form 
connections with neighboring cells. For these experiments, we kept an untreated control of both 
the naïve MCF-7 cells and the population that had become stably spiky at about 30% spiky cells. 
To create the treated groups, we took a sample from each of the untreated populations and 
treated them with 500 nM doxorubicin for a 24-hour period. Over the course of the recovery 
from this treatment, we assessed the differences between the populations in four characteristics 
associated with tumor aggression: proliferation rate, dose response, invasive potential, and E-
cadherin expression. Scale bars are 400 m. 
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Cell Imaging 
To image the cells multiple times per week, we used an EVOS light microscope. When 
imaging, we acquired several images with both the 4X and 10X objectives. To determine total 
magnification, we multiply the magnification of the objective by the magnification of the 
monitor by the magnification of the camera-video adaptor. Because there is no glass in the 
microscope mount, the camera-video adapter magnification is 1X.
18
 Assuming a 15-inch display 
is similar to a 17-inch display, the magnification of the monitor is approximately 54.1X.
19,20
 
Therefore, the total magnification of the 4X objective is approximately 216.4X and the total 
magnification of the 10X objective is approximately 541X.  
 
Quantification of Proliferation  
To test proliferation rate, we counted the number of cells in the flasks that were passaged 
each week for the Invasion and Dose Response experiments, two flasks per group. Because these 
flasks were different sizes and were counted on different days of the week, I could not average 
the cell counts in order to find proliferation. Instead, I divided the cell count by the amount of 
cells that had originally been seeded onto that plate and then raised this to 1/(days since seeding). 
This gave the cell proliferation per day, and this was averaged with the other values of 
proliferation per day that were found for that cell type that week.  
 
Invasion Assay 
Each week of doxorubicin recovery, the invasion assay was performed on cell samples 
from the four groups – untreated normal, stable spiky, treated normal, and treated spiky – using 
the Trevigen CultureCoat Low BME Cell Invasion Inserts (Cat #3481-024-01). Each week, two 
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inserts were used per group, except in weeks seven and eight. In those weeks, I began using three 
inserts per group in order to calculate standard deviations. We prepared the invasion inserts 
according to the manufacturer’s instructions. Inserts were placed in a tissue culture-treated 24-
well plate, and  80 µL of serum-free media was added to the top of each insert. The serum-free 
media was made by combining 500 mL of MEM (Gibco Lot #1663071), 5.6 mL Pen-Strep 
(Gibco Lot #1601706), and 0.5 g of Bovine-Serum Albumin (Fisher Scientific Lot #130710). 
Following an hour incubation at 37C, 40 µL of cell solution at a concentration of one million 
cells/mL was placed on the top of each invasion insert. The bottom of each well was filled with 
360 µL of complete media, and the plates were placed in the incubator for 24 hours.  
After 24 hours, the plate was removed from the incubator and we fixed and stained the 
cells. We stained the cells with crystal violet because it binds to cellular proteins and stains the 
cells purple, which made the cells visible for counting under the microscope. To do this, we used 
the 24-well plate with the invasion inserts and media in eight wells, leaving eight of the wells 
empty and adding 70% ethanol to the other eight wells. In an additional 24-well plate, we filled 
eight of the wells with 0.2% Crystal Violet solution in DI water and sixteen wells with DI water. 
We took the inserts out of the wells with the media and used a sterile cotton-tipped swab to 
remove the media and cells from the top of the membrane. Being careful not to touch the bottom 
of the membrane, we then placed the inserts in the 70% ethanol solution and allowed them to 
soak for 15 minutes. This fixed the cells to the membrane. The tops of the membranes were dried 
with cotton again, and they were placed in the empty wells to dry for 15 minutes. Then they were 
placed in the Crystal Violet for 15 minutes, then washed in the two sets of DI water for 10 
minutes each, and the membrane was dried with cotton between each of these steps. These 
rinsing steps washed the excess crystal violet, which had not bound to the cells, off the 
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membrane. Finally, the inserts were removed from the final wash and the tops of the membranes 
were dried again, and they were placed in the empty wells until they were completely dry, at 
least 15 minutes.  
Typically, the stained invasion inserts were left overnight to completely dry. At that 
point, they were imaged for counting the number of invading cells, which appeared as dark 
purple, roughly spherical shapes. Six images were taken of each insert: one image of the whole 
insert with the 4X objective (approximately 216.4X total magnification), and five images in a 
cross pattern with the 10X objective (approximately 541X total magnification). The number of 
invading cells was counted in each 541X image, and each week the counts for each treatment 
group were averaged. These average counts were then plotted on a bar graph. Standard 
deviations were calculated for weeks seven and eight when three invasion wells were used. 
 
Staining Cells 
We stained the cells for E-cadherin seven weeks after they had been treated with 
doxorubicin, and we performed the staining on all four treatment groups: untreated and treated 
normal and stable and treated spiky. Several days before staining, 100,000 cells were seeded into 
each well of a 12-well tissue culture-treated plate which had round glass cover slips attached to 
the bottom. There were two wells of each treatment group. To perform the E-cadherin staining, 
we followed a general immunostaining protocol. Cells were fixed with 4% paraformaldehyde for 
30 minutes, washed twice with 500 µL of PBS for five minutes, and blocked with 800 µL of 3% 
BSA/0.1% TritonX-100 (Sigma Lot #SLBF4531V)/PBS for 30 minutes at room temperature. We 
then washed three times with 150 µL of washing solution (0.1% TritonX-100/PBS) for five 
minutes at room temperature. The next step was to add the primary antibody. Each well was 
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incubated at room temperature for 90 minutes with 150 µL of rabbit E-cadherin antibody 
(GeneTex Rabbit monoclonal antibody [EP700Y]) diluted in 1% BSA/PBS at a ratio of 1:500. 
We then washed three times for five minutes each with the washing solution at room temperature 
before adding the secondary antibody (Alexa Fluor 568 Donkey Anti-Rabbit Ref# A10042), 
which was diluted in 1% BSA/PBS at a 1:200 ratio. We added 150 µL to each well and allowed 
the plate to incubate for 60 minutes in the dark at room temperature. We then washed three times 
for five minutes each with the washing solution at room temperature. We then stained with 4’,6-
diamidino-2-phenylindole (DAPI) at a concentration of 1 µg/mL for five minutes. DAPI binds to 
DNA and stains the cell nucleus with blue fluorescence. Next, we rinsed twice for five minutes 
with PBS at room temperature.  
The cover slips were removed from the wells with tweezers, mounted to microscope 
slides using fluoromount, and sealed with nail polish. Imaging was performed with the EVOS 
fluorescent microscope using the 60X objective (approximately 4050X total 
magnification).
18,20,21
  
To quantify the E-cadherin levels, I took between eight and 10 4050X images of each 
treatment group. For each of these images, I counted the total number of cells in each image 
which were close enough to other cells to form junctions. I then counted the number of cells in 
each image which formed at least one junction with another cell, and divided this by the total 
number of cells to find the percentage. I then averaged these percentages from the different 
images to find the average percentage of cells with at least one junction in each cell population.  
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Dose Response Assay  
Each week of the doxorubicin recovery, a 15 cm plate of each of the conditions 
(untreated normal, stable spiky, treated normal, and treated spiky) was passaged. These were 
seeded into 12-well plates, with 100,000 cells of each type plated into six wells. After two days 
of culturing, we treated the cells with doxorubicin for 24 hours. Each treatment group received 
six doses, with a different dose to each of the six wells. These doses of 0 µM, 8 µM, 24 µM, 48 
µM, 96 µM, and 192 µM were achieved by diluting the 2048 nM doxorubicin with MCF-7 
media. After 24 hours, the doxorubicin was removed and the cells were passaged and analyzed 
using the Cellometer (Nexcelom Cellometer K2 Image Cytometer).  
The Cellometer was used to find the percentage of viable cells in each group. Acridine 
Orange/Propidium Iodide (AO/PI, Nexcelom Lot #1507 13-04-1) was used to stain the live cells 
green and the dead cells red. After spinning the cells down, the media and trypsin were aspirated, 
leaving approximately 20 µL of solution in each tube. The MCF-7 Live/Dead Assay was 
performed with a mixture of 10 µL of AO/PI and 10 µL of cell suspension, and the results were 
given as number of live cells, number of dead cells, and percent viability. These were graphed 
for each week.  
To obtain the LD50 from the viability percentages at each dose, we fit these values to the 
following equation: 
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝑀𝑎𝑥 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦
1 +  𝑒𝑠𝑙𝑜𝑝𝑒∗(𝐷𝑜𝑠𝑒−𝐿𝐷50)
 
In this equation, viability is the percentage of cells alive after a 24-hour treatment with 
doxorubicin, max viability is the viability of that population for the 0 µM doxorubicin dose 
during that week, slope is the slope of the viability curve, and dose is the variable dose of 
doxorubicin applied to the cells in µM. To fit the data to this equation, we used the solver 
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function in Excel to minimize the difference between the actual viability and the estimated 
viability from the equation. After obtaining the LD50s for each treated population at each 
timepoint, they were graphed over the weeks of recovery from the original treatment. The week 
zero timepoint was calculated by averaging the LD50 values for the untreated controls from five 
timepoints.  
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Results 
 
Treatment of Cells with Doxorubicin and Imaging Phenotypes During Recovery 
from Doxorubicin Treatment 
 
After MCF-7 cells have been treated with doxorubicin, many of the cells die off, and they 
continue to die at high rates through five weeks after treatment. The cells which survive are those 
we continue to culture, and the survivor cells are the ones which divide in order to repopulate the 
culture. Of these survivor cells, many take on phenotypes other than the typical MCF-7 epithelial 
morphology. In the typical MCF-7 population, the majority of cells form a cobblestone pattern, 
in which the cells form close connections with the cells around them. Other morphologies that 
arise at high proportions after treatment with doxorubicin include the spiky cell morphology, in 
which the cells form long, spindly projections and do not form close connections with the 
neighboring cells. Another phenotype that arises is the "fried egg" morphology. These cells are 
much larger and flatter than the typical MCF-7 cells. They also do not appear to form close 
connections with the neighboring cells, and some of them appear to be multi-nucleated.  
Figure 2 demonstrates the changes in the proportions of subpopulations within the MCF-
7 population after treatment with doxorubicin. Though the non-typical subpopulations are 
observed in the group without treatment, the majority of the cells have the typical morphology 
and form the normal cobblestone pattern. In Figure 2, the "Other" category includes the spiky 
phenotype as well as other non-typical MCF-7 morphologies such as the fried egg cells. These 
“other” cells also included cells which could not be classified as normal, fried egg, or spiky. 
These included cells which appeared to be transitioning between the spiky and fried egg 
morphologies as well as cells which could not be identified because they were not lying flat on 
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the plate. To identify spiky cells, we looked for cells without close connections, which are not 
flat to the plate like the fried egg cells and which have a curved shape or thin projections of 
cytoplasm.  
Two weeks after treatment with doxorubicin (Figure 2), the majority of the cells are the 
other phenotypes, and these other phenotypes persist at higher-than-normal proportions 
(approximately 40-60%) throughout the 14 weeks tested post-treatment. Although this data is 
from only one experiment, the entire time course has been reproduced several times in the lab 
over the past two years and the same pattern emerges.  
For the spiky induction experiment, we found that after about eight weeks, all 16 of the 
flasks which had been passaged each week looked relatively normal in cell morphology. 
However, we found that the flasks which had been left alone began dividing again after treatment 
more quickly than did the passaged flasks, and two of these untouched flasks had interesting 
populations of cells. One of the flasks had many of the big fried egg type cells. After several 
weeks of passaging these though, the cell population returned back to the normal phenotype. A 
second flask had a higher proportion of the spiky cells. We used the UnipicK to isolate spiky 
cells, and we plated these cells into a three wells of a 12-well plate. Two of the wells had 
approximately 100 cells and one of the wells had approximately 30 cells. We found that after 
several weeks these cells returned to relatively normal morphologies. In that same time, 
however, the 10 cm dish with the rest of the population continued to have high proportions of 
spiky cells.   
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Figure 2 | Quantification of Morphology Changes Arising from Doxorubicin Treatment. In 
these experiments, three plates of MCF-7 cells were treated with 500 nM of doxorubicin for 24 
hours and three plates were left untreated, and the proportions of the different morphologies were 
quantified over the 14-week recovery period from the treatment. For each time point, one 
representative image was counted for either two or three plates, and the results from the different 
plates were averaged. 
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Proliferation During Recovery from Doxorubicin Treatment 
Proliferation rate measures how quickly the cells are dividing, and this value was 
measured in the four treatment groups over the course of recovery from the doxorubicin 
treatment by counting several plates of cells each week (Figure 3). The untreated groups had 
fairly consistent proliferation, with the stable spiky cells having slightly higher (by 1-5% in most 
weeks) proliferation rates per day. In the treated groups, the cells were still dividing faster than 
they were dying in the first week, but in weeks two through five they were dying off more 
quickly than they could divide. Over the course of the recovery from the doxorubicin treatment, 
the two treated groups had very similar proliferation rates. Because the plotted growth rates are 
for average growth per day, small differences are magnified over the course of a week. While the 
stable spiky cells were growing only slightly faster than the untreated normal each day, in many 
of the timepoints the stable spiky had approximately 1 million more cells in a T-75 flask than the 
untreated normal cells. In the treated groups, there was a large jump in proliferation between 
weeks five and six – at this point the cells went from negative net growth rates to proliferation 
rates similar to the untreated controls. In weeks seven and eight, the proliferation rates continued 
to approach the untreated controls, demonstrating that the doxorubicin treatment did not appear 
to have a lasting effect on proliferation.  
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Figure 3 | Proliferation During Recovery from Doxorubicin Treatment. Proliferation rate is 
a measure of how quickly the cells are dividing. To create this figure, each week we counted at 
least two plates of cells from each treatment group. We then divided this count by the number of 
cells that had originally been seeded into the dish and raised this result to 1/(days since seeding). 
This gave us the proliferation per day, and we averaged the values obtained from two flasks each 
week.  
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Drug Sensitivity During Recovery from Doxorubicin Treatment 
Drug sensitivity was tested over a wide range of drug concentrations and is displayed in 
Figure 4 as LD50 over time. LD50 is a measure of the dose of doxorubicin needed to kill 50% of 
the cells during that week. More resistant cells have higher LD50s, meaning a higher 
concentration of the drug is required to kill off 50% of the population.  
The average LD50 for the untreated normal group was 68.7 µM, and the average LD50 of 
the stable spiky group was 52.4 µM. These values mean that the stable spiky were actually 
slightly less resistant than the normal group, which is opposite of what we expected. The 
standard deviation for the LD50s of the untreated normal population was 5.9 µM, while the 
standard deviation for the LD50s of the stable spiky population was 10.9 µM. These standard 
deviations are relatively small, as the LD50s of the treated populations ranged from 37 to 200 
µM, demonstrating that the untreated populations both remained relatively consistent over the 
course of the eight weeks. This is expected because these were the control groups. This result 
confirms that the assay was performed in a consistent manner over the course of the eight weeks.  
The most notable aspect of Figure 4 is that the treated spiky became highly resistant in 
the first week after treatment, while the treated normal did not become highly resistant until the 
second week after treatment. The treated normal group responded to the doxorubicin treatment 
with little change after one week, but in the second week after treatment, the population had 
become more resistant by more than two times. Over the course of recovery, the resistance of 
both groups declined back to the untreated value. Because the final LD50s of the treated groups 
are similar to the average LD50s of the untreated groups, the doxorubicin treatment did not 
appear to have a lasting effect on the drug sensitivity of the normal population. Additionally, 
23  
 
because the treated spiky group became resistant faster than the treated normal group, the stable 
spiky cells appear to be primed to become resistant more quickly than the normal MCF-7 cells.  
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Figure 4 | Drug Sensitivity During Recovery from Doxorubicin Treatment. Resistance to 
doxorubicin is measured in LD50, which is the concentration of doxorubicin in M it takes to 
kill exactly 50% of the cells. Each week of this experiment, each treatment group was given six 
doxorubicin concentrations over the range of 0 M to 192 M. After 24 hours, the viability of 
the cells in each concentration was assessed, and this curve was used to estimate the LD50.  
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Invasive Potential of Cells Following Doxorubicin Treatment 
The invasive potential of all four treatment groups was evaluated by measuring cell 
migration through a polycarbonate filter with 8 µm pores coated with a thin basement membrane. 
The percent of cells migrating across the filter was determined by crystal violet staining of fixed 
cell populations after 24 hours (Figure 5). As shown in Figure 5, aside from some unusual data 
points in weeks one and six, the untreated normal cells stayed relatively consistent in their 
invasive potential over the course of the eight weeks. This is expected, since this was the naïve 
MCF-7 population which had never received any doxorubicin treatment. The treated normal cells 
slightly increased in their invasive potential immediately after the doxorubicin treatment, then 
fell back down below the values of the untreated population for several weeks before settling 
back in the last two weeks to be very close to the untreated invasion values. The weeks in which 
the treated normal cells had low invasive potential, weeks three through five, correspond with the 
weeks in which the cells were dying off most quickly (Figure 3).  
The stable spiky population had invasion values that varied across each week. This group 
was a control group which we did not expect to have large differences in invasion because it had 
not been treated since the spiky population became stable. However, the stable spiky population 
was quite consistently more invasive than the untreated normal population. The treated spiky 
population decreased in invasiveness, compared to both untreated populations, in the first weeks 
after treatment. Over the weeks, their invasiveness steadily increased, before settling back down 
to a value similar to the untreated normal population in the eighth week. By examining the spiky 
cells under the microscope over the course of the eight weeks after treatment, we saw that the 
treated spiky cells began to approach a population intermediary between the naïve and stable 
spiky populations. There were more spiky cells in the treated spiky population than in the naïve 
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untreated population, but the treated spiky population had fewer spiky cells than the stable spiky 
population. Therefore, the invasion results showing that the treated spiky were often 
intermediary between the untreated normal and stable spiky populations align with these 
observations.  
Additionally, by examining both treated populations, we see that the doxorubicin 
treatment does not produce a lasting increase in invasive potential. Though there are several 
weeks in which the treated population had a higher invasive potential than the corresponding 
untreated population, particularly at the beginning of the recovery of the treated normal group, 
by the end of the recovery at eight weeks the treated populations have similar invasion as the 
untreated population. Treatment with doxorubicin does not appear to have a long-term effect on 
the invasive potential of the MCF-7 cells.  
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Figure 5 | Invasive Potential During Recovery from Doxorubicin Treatment. Invasive 
potential was measured using invasion well inserts with a polycarbonate membrane with 8 m 
pores coated in thin basement membrane. Each week for weeks one through six, cells of each 
treatment group were placed in two invasion well inserts with serum-free media which were 
placed in wells which contained complete media. In weeks seven and eight, three inserts were 
used for each group. After 24 hours, the membranes were stained with crystal violet fixed cell 
stain and imaged. To obtain representative images from the wells, we took five images of each 
well with the 10X objective (541X total magnification) in the same cross pattern: one in the 
middle, one directly above this, one below the first image, one to the left of the first image and 
one to the right of the first image. The number of crystal violet-stained cells was counted in each 
image, and the counts from the 10 images for each treatment group were averaged. The error 
bars in weeks seven and eight are one standard deviation.     
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Staining for Biomarkers Labelling Resistant Cells 
The cell-cell junction marker E-cadherin was used to examine the differences in cell 
connections between the treatment groups (Figure 6). This staining was performed seven weeks 
after the doxorubicin treatment, so in many respects the treated cells were recovered back 
similarly to the untreated controls. In the images, the blue stain is DAPI, identifying the cell 
nuclei, and the red stain is the E-cadherin. Close cell connections appear as a solid but thin red 
line. By examining representative images, we see that the normal groups, both treated and 
normal, have many solid cell connections. In contrast, the spiky cells have fewer cell-cell 
junctions, though the treated spiky group appears to be intermediary between the stable spiky 
population and the normal groups. In the normal groups and even the stable spiky group, the vast 
majority of the cell junctions that appear are solid red lines. However, in the treated spiky group, 
most of the cell connections appear as wavy, incomplete lines. It appears that while there is much 
more E-cadherin in the treated spiky population than in the stable spiky group, the cell junctions 
are not solid, continuous junctions as they are in the other populations. By quantifying the 
percent of imaged cells which had at least one junction with another cell, we found that the 
normal groups and the treated spiky group were quite similar. In the untreated normal 
population, 82.5% of the cells had at least one junction, in the treated normal population that 
percentage was 77.9%, and for the treated spiky it was 79%. However, in the stable spiky 
population, only 1.9% of the cells had a junction with at least one other cell.  
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Figure 6 | Immunocytochemistry Staining for E-Cadherin. E-cadherin is a cell-surface 
marker for cell-cell junctions. In these images with 4050X total magnification, DAPI, a cell 
nucleus stain, is blue and E-cadherin is red. For this experiment, we stained two slides of each 
treatment group, 7 weeks after the cells were treated with doxorubicin. To obtain representative 
images of the staining, we took five random images of slides from each treatment group. For 
counting, we took between eight and 10 images of each treatment group. A) Untreated Normal 
B) Stable Spiky C) Treated Normal D) Treated Spiky. Scale bar is 50 m.  
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Discussion and Conclusion 
From the lab’s first studies on drug-induced phenotypic transitions, a key finding was that 
a short, 24-hour exposure to doxorubicin had lasting results on cell phenotype 14 weeks later. 
Though the majority of the plates return back to normal phenotype after recovering from 
treatment, there are some rare cases in which one of the other morphologies stabilizes at a higher 
proportion, such as in the stable spiky population. In this case, the effects of the doxorubicin 
lasted even longer than 14 weeks and induced a change in the cells which was maintained over 
approximately 30 passages. For patients, this implies that even one dose of chemotherapy can 
have long-lasting impacts on both the tumor and the patient's healthy cells. The first dose of 
chemotherapy could be altering the composition of the tumor, impacting how it will respond to 
the next dose, even if that dose is months later, and possibly increasing the resistance of the 
tumor to the chemotherapeutic agent. Future studies which could improve upon these results 
could find another way of characterizing the cells that were transitioning between phenotypes 
and the ones that were difficult to count. Additionally, this data is compiled from my cell counts 
as well as the counts of two other undergraduates, so the counting method is not completely 
uniform, which could affect the result.  
Though the difference in cell proliferation per day between the untreated normal and the 
stable spiky population appears small, in many weeks it becomes a difference of about 1 million 
cells once it is multiplied out over the course of the week. Proliferation is one of the 
characteristics of tumor aggression, and the fact that these stable spiky cells are growing more 
quickly shows that they are more aggressive than the typical MCF-7 cells. Notably, however, the 
treated spiky do not show a considerable difference in proliferation over the treated normal cells, 
except possibly in two timepoints (Figure 3). Additionally, the proliferation levels of the treated 
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groups appear to be approaching the pre-treatment levels by the end of recovery. This 
demonstrates that while the stable spiky population does appear to be more aggressive, a 
treatment with doxorubicin does not increase this aggressiveness and may decrease it, at least in 
terms of proliferation.  
This data for cell proliferation per day is not completely accurate. Some of the treated 
plates were left in the same vessel without passaging for several weeks, and to find the cell 
proliferation per day we used the number of days since seeding the cells. This assumes that the 
cell proliferation per day was about the same over those several weeks, which we know is not 
true because the cells were dying off more quickly in the middle weeks of recovery. Future 
experiments could make this data simpler and more accurate by using the same size vessel for 
each cell type and passaging the plates each week. Alternatively, future experiments could use an 
assay to quantify proliferation such as staining for Ki67. 
The result that the stable spiky cells are less resistant to the doxorubicin is surprising 
(Figure 4). However, the LD50 values of the two controls are quite similar to each other. 
Because the treated spiky population becomes resistant so quickly after treatment, we conclude 
that the stable spiky cells are primed to become resistant more quickly than the normal cells. 
From these results we see that the populations return to resistance levels close to those of the 
controls by the end of recovery. Future experiments could then treat these recovered populations 
again to determine whether the treated normal population is now primed to become resistant 
more quickly and whether the treated spiky population becomes even more resistant or if another 
treatment reverses this resistance.  
The invasion assay yielded several interesting results (Figure 5). First, the stable spiky 
population showed a large amount of variation in invasive potential. This variation implies that 
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the population may be shifting slightly over time, with varying proportions of the spiky 
phenotype over the weeks. However, there were no noticeable differences in the stable spiky 
population morphologies over the course of the experiment. The untreated normal population, 
which had relatively consistent invasive potential, had incredibly high invasion in week six, and 
this abnormally high value came from one invasion well. The high rate of invasion could have 
been due to a flaw in the well or a larger number of cells being seeded into the well. It seems 
unlikely that this high invasion in one well is a true result, but future studies could confirm this 
conclusion. For weeks one through six, we used two invasion wells for each population, and in 
the seventh week we switched to using three invasion wells each. Future experiments should use 
three invasion wells for each population for each timepoint, so that standard deviations can be 
found in order to assess the variability of the invasive potential at all timepoints. Taking an 
average of three wells each week may also help to reduce the variability of the untreated 
populations between weeks.  
The treated normal population became more invasive than the control in the two weeks 
directly after treatment (Figure 5). This is expected because we predicted that the doxorubicin 
treatment would increase the aggressive characteristics of the cells. A surprising result was that 
the doxorubicin treatment had the opposite effect on the stable spiky cells, making them less 
invasive. By weeks seven and eight, the invasiveness of the treated spiky was beginning to 
approach that of the stable spiky. This aligns well with the morphological cellular changes I 
observed, that the treated spiky cells recover to a state in between that of the typical MCF-7 cells 
and the original stable spiky population (Figure 6). 
The E-cadherin results support the hypothesis that the stable spiky cells are more 
aggressive (Figure 6). As a cell-cell junction marker, high levels of E-cadherin mean the cells are 
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tightly connected to each other. When cells have less E-cadherin expression, they are less 
connected to their neighbors and therefore can become mobile more easily. The fact that the 
stable spiky cells have much less E-cadherin corresponds to the fact that they have a much 
greater invasive potential and demonstrates that they are more aggressive. Invasion and motility 
are key aspects of tumor progression, as more advanced tumors are able to spread and eventually 
become metastatic. Future studies should be done to assess the E-cadherin levels earlier in the 
recovery from the doxorubicin treatment. By seven weeks, the treated normal are very similar to 
the untreated normal, and the treated spiky have many of the incomplete junctions that are not 
found in the stable spiky cells. Performing this staining earlier in the recovery could help us to 
understand how E-cadherin levels, and by extension mobility and aggression, fluctuate during 
the recovery from the treatment.  
The motivation behind this research is to improve cancer treatments. The goal is to 
identify a subpopulation of survivor cells which seem to confer tumor aggression and 
chemotherapeutic resistance and the epigenetic changes that are exhibited by this subpopulation. 
It has been found that just the up-regulation or down-regulation of certain genes, without any 
actual mutations, can confer increased resistance to cells.
11
 Because these changes are epigenetic, 
rather than genetic, they are reversible.
8
 Then, in order to increase the effectiveness of 
chemotherapeutics, the gene expression of the subpopulation could be altered back to the gene 
expression of the normal population before the drug is administered, in order to reduce the 
likelihood of resistant cells emerging. For example, siRNA could be used to block upregulated 
genes. Studies of melanoma, another type of cancer, have found that though the majority of 
tumor cells are the main, fast-growing population, there is also a subpopulation of "slow-cycling, 
self-renewing" tumor cells.
22
 Roesch et al. hypothesized a similar idea to ours – that in order to 
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have a greater therapeutic effect, it would be necessary to target the slow-cycling subpopulation 
– though there are differences between their subpopulation and the spiky cells, such as the fact 
that the spiky cells are highly proliferative.
22
  
Another phenotypic state that breast tumor cells have been found to exhibit is that of the 
stem-like cancer cell.
23
 These cells have increased drug resistance and tumor-seeding ability, and 
Gupta et al. found that it is not only possible for these stem-like cells to transition to other 
phenotypes but that it is also possible for non-stem cells to transition to the stem-like phenotype. 
They recommend that to treat breast cancer, it would be necessary to target both the bulk 
population and the stem-like cells, or to prevent the transition from the non-stem phenotype to 
the stem-like phenotype.
23
 Based on our experiments, it appears that the spiky cells may be 
exhibiting stem-like characteristics and may have undergone a transition from a non-stem 
phenotype to a stem-like phenotype.  
The epithelial to mesenchymal transition is affiliated with both invasive and metastatic 
potential, as well as increased aggressiveness, in carcinoma cells such as breast cancer cells.
24
 
Some of the characteristics of EMT include decreased intercellular adhesion (E-cadherin and 
occludins), fewer epithelial markers such as cytokeratins, more mesenchymal markers including 
vimentin, morphological changes to fibroblast-like or spindly morphology due to cytoskeleton 
reorganization, and an increase in mobility and invasiveness.
24
 Several of these characteristics 
are ones we observed in the stable spiky population: decreased E-cadherin levels, spindle-like 
projections, and increased invasiveness. Because of these similar characteristics, it may be true 
that the spiky cells are MCF-7 cells that have undergone EMT. Previous studies in melanoma 
cells have found that resistance is not only related to EMT but that cells undergo EMT in order to 
become resistant to chemotherapeutics.
25
 This may be what is occurring in the MCF-7 breast 
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cancer cells. EMT markers have been found in breast carcinoma biopsies, and these markers are 
associated with increased aggression and poor prognosis.
24
 Transitioning to the mesenchymal 
phenotype could allow the cells to survive the doxorubicin treatment, and because this is a 
reversible process they could transition back to the epithelial phenotype later in recovery in order 
to repopulate the normal morphology. The stable spiky population may be a population that has 
established an equilibrium with a higher proportion of mesenchymal cells. Future studies should 
further confirm this by examining protein and gene expression related to EMT and the 
mesenchymal phenotype. Additionally, other experiments in the lab are examining the other 
phenotypes, such as the fried egg cells, in order to understand what role those cells have in tumor 
aggression and resistance.  
The results from the proliferation, invasion, and E-cadherin experiments (Figures 3, 5 and 
6) show that the doxorubicin treatment appears to remove the mesenchymal-like qualities of the 
spiky cells. This implies that the doxorubicin treatment can push the cells in either direction of 
the transition – either to mesenchymal cells or in the other direction, toward epithelial cells. 
Though in these experiments the treated spiky cells began to respond similarly to the normal 
cells in many of these experiments, morphologically they appeared intermediary between the 
original stable spiky and the untreated normal. They continued to have higher-than-normal 
proportions of spiky cells. However, previous experiments in the Brock lab have found that the 
treated spiky population recovered to a much more normal distribution of morphologies. The 
reason for this difference in reaction to the doxorubicin treatment is unclear and will be a focus 
of future follow-up studies in the lab.  
In all of my experiments, I was looking at survivor cells that have escaped a substantial 
dose of a chemotherapeutic drug. Other researchers termed such cells "drug-tolerant persisters" 
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(DTPs), which are a small group of reversibly resistant cells which are able to survive after most 
of the population has been killed.
10
 Sharma et al. found that cell populations can be reversibly 
resistant to drugs by keeping a distinct subpopulation of cells of a more resistant phenotype. This 
subpopulation protects the population by surviving and repopulating after the stress is removed.
10
 
Other studies of doxorubicin treatments have focused on long-term low doses rather than one 
pulse of treatment.
26
 Fairchild et al. used these long, low doses to create doxorubicin-resistant 
cell lines. These experiments that we performed, however, characterize a short-term, high dose 
of chemotherapeutic agent, which more closely mimics the clinical scenario. Rather than 
examining the effects of a long-term dose on the cells, we are examining how cells adapt or 
escape from a pulse of treatment.  
My experiments characterizing the spiky cells fit into the larger context of other work in 
the Brock lab. One future direction other researchers will take these studies is to characterize the 
cells' response to a second dose of doxorubicin. After allowing the treated populations to recover 
for about eight weeks, they will be treated again and similar experiments characterizing tumor 
aggression will be performed over the recovery from this treatment. In addition, the epigenetic 
changes that lead to the spiky phenotype will be characterized, to better understand if the cells 
did undergo an epithelial to mesenchymal transition or reverted to a stem-like phenotype. These 
experiments may lead to a better understanding of cancer cell resistance to chemotherapeutics, 
which could in time help to improve therapeutic treatment of these tumors.  
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